- Through 2026 the FDA has issued a steady series of warning letters to online peptide sellers, including Gram Peptides and Pink Pony Peptides in March and Wholesale Peptide in June.
- The recurring finding: unapproved drugs such as semaglutide, tirzepatide, retatrutide and BPC-157 sold with “research purposes” labels while being marketed for human use.
- The FDA’s standing advice is unchanged: products of unknown quality, no legal route, real risk.
What happened
Warning letters are the FDA’s formal notice that it considers a business to be breaking the law. In 2026 those letters have arrived in a rhythm: on March 31 the agency wrote to Gram Peptides for offering retatrutide, tirzepatide and bacteriostatic water for injection, and to Lovega LLC, doing business as Pink Pony Peptides, for products sold as “GLP-2 TZ” and “GLP-3 RT”. In June, Wholesale Peptide received its letter for products including Prostamax and Gonadorelin. Earlier letters in the same campaign covered Prime Peptides, USApeptide.com and GLP-1 Solution.
The pattern across the letters is consistent. Sellers label vials “for research purposes only” or “not for human consumption”, then market them with dosing guidance and health claims aimed squarely at consumers. The FDA treats these as unapproved new drugs introduced into interstate commerce, and it has paired the letters with a standing consumer advisory on unapproved GLP-1 products of unknown quality.
Why it matters
Independent analyses of grey-market peptides have repeatedly found mislabeling, wrong doses and contamination. The letters will not shut down the category overnight, but they map exactly where the risk sits: outside the prescription system there is no verified identity, purity or sterility, whatever the label promises. If you are evaluating any peptide product, the seller’s regulatory standing is the first checkpoint, before price and before reviews.
Frequently asked questions
What does a warning letter actually do?
It is formal notice, not a fine or a shutdown. But it documents violations, demands correction, and often precedes seizures, injunctions or import refusals if the seller does not respond.
Does “research use only” labeling make sales legal?
Not when the marketing targets human use. The FDA’s letters state that the disclaimer does not change what the products are: unapproved drugs.
How do I check a seller?
Search the FDA’s warning-letter database for the company name, and treat any consumer-facing shop selling injectable “research” peptides as a red flag. Our provider guide below walks through the full checklist.